Oliveto Joseph 4

What Happened
Joseph Oliveto, President, CEO and a director of Milestone Pharmaceuticals (MIST), received two equity awards on February 2, 2026: a grant of 679,000 option-based derivative shares and a grant of 453,000 restricted stock units (RSUs). Both awards were reported at $0.00 per share (typical for compensation grants) and are derivative/contingent awards rather than open‑market purchases or sales.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
• Awards: 679,000 shares (derivative option award) and 453,000 restricted stock units (RSUs). Reported price: $0.00.
• Vesting for the option award (F1): 1/4 vests on Feb 2, 2027, then 1/36 of the remaining shares vest each month thereafter, subject to continued service.
• RSU details (F2, F3): Each RSU converts to one common share; 1/4 of RSUs vest on each of Feb 2, 2027, 2028, 2029 and 2030, subject to continued service.
• Shares owned after the transaction are not specified in this filing. No exercise, sale, tax withholding, or 10b5‑1 plan is indicated in the reported items.

Context
These are standard compensation grants to a company executive. The option award is not an exercise (no shares were purchased or sold); the RSUs are a contingent right to receive common shares if vesting conditions are met. Grants like these are common in executive compensation and do not by themselves indicate trading sentiment.